Genetic disruption of circadian function alone indirectly suppresses GPR68 and is sufficient to significantly attenuate CKD-associated cardiac inflammation and fibrosis, providing genetic proof-of-concept for therapeutic targeting of GPR68. This evidence concerns the gene GPR68 and chronic kidney disease.